MATHEW TILSON: Open Payments
NPI 1467763813 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,808 in 187 payments from 36 companies in 2025. Trend: 2023 $7,471 · 2024 $3,578 · 2025 $3,808
Food & beverage: $3,696Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 55 | $790 |
| Gilead Sciences, Inc. | 11 | $344 |
| Novo Nordisk Inc | 17 | $275 |
| AstraZeneca Pharmaceuticals LP | 13 | $263 |
| Vanda Pharmaceuticals Inc. | 10 | $198 |
| PFIZER INC. | 8 | $172 |
| Lilly USA, LLC | 10 | $164 |
| Teva Pharmaceuticals USA, Inc. | 2 | $134 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $133 |
| Axsome Therapeutics, Inc. | 5 | $131 |
Products named: VRAYLAR, UBRELVY, FANAPT, FASENRA, CAPLYTA, ELIQUIS, Auvelity, LINZESS.
Industry payments across WI — which companies pay providers there.
